Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation

Molecular Therapy — Nucleic Acids(2022)10.1016/j.omtn.2022.03.022Source: DataRank Database

CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation is a research paper published in Molecular Therapy — Nucleic Acids (2022). On theSindex it has a DataRank of 0. It has been cited 50 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access50 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)OA: goldTopics (22)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Agnieszka Molisak,Florian Perrin ORCID,Linn Streubel-Gallasch,Sarah M. Fayad ORCID,Daniel Y. Kim ORCID

Live enrichment

PubMed:35505961

Vetenskapsrådet

Grant: 2018-03075

Vetenskapsrådet

Grant: 2021-02793

Deutsche Forschungsgemeinschaft

Grant: 417577129

National Institutes of Health

Grant: AG015379

National Institutes of Health

Grant: AG044486

National Institutes of Health

Grant: R35 GM118158

Swedish Research Council

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5R35GM118158-03

Evolution, Optimization, and Application of Genome Editing Technologies

National Institutes of Health

Grant: 5R01AG044486-04

Role of PS1 in neurodegeneration

National Institutes of Health

Grant: 2P01AG015379-11

Presenilin Biology and the Mechanism of Alzheimers Disease

NIA NIH HHS

Grant: P01 AG015379

NIA NIH HHS

Grant: R01 AG044486

NIA NIH HHS

Grant: RF1 AG044486

goldLicense: cc-by

publisherhttp://www.cell.com/article/S2162253122000713/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2162253122000713?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2162253122000713?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9043867

repositoryhttp://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-475572

Fields of Study

0301 basic medicine03 medical and health sciences

Keywords

Neurologigene editingMT:: RNA/DNA editingMedical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)off-target effectsRM1-950amyloid-βMedicinsk genetik och genomikMedical Genetics and GenomicsNeurologyprotein conformationMTpresenilin 1fibroblastsRNA/DNA editingOriginal ArticleTherapeutics. PharmacologyCRISPR-Cas9Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)Alzheimer’s disease

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease

10.6084/m9.figshare.21129966.v1figshare

Additional file 1 of CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease

10.6084/m9.figshare.21129966figshare